Batavia Biosciences releases ‘Amalia,’ a novel manufacturing facility in Leiden, The Netherlands, enhancing their capability in viral vaccine and vector production.
Batavia Biosciences has announced the launch of ‘Amalia,’ a new GMP-ready manufacturing facility in Bilthoven, Netherlands.
This facility marks a significant advancement in the company’s ability to produce viral vaccines and viral vectors for clinical manufacturing. Menzo Havenga, CEO of Batavia Biosciences, highlights that Amalia aligns with the company’s mission to bring medical solutions from the lab to patients, especially in the context of epidemic preparedness.
The facility, equipped with advanced technology and adhering to high-quality standards, is set to play a crucial role in vaccine and viral vector development and production.
Amalia is part of Batavia Biosciences’ broader expansion strategy, with further developments anticipated, including a larger facility in Leiden.
For more details and future updates from Batavia Biosciences, please refer to their official announcements.
Leiden, 8 January 2026 – Two scientific projects from Leiden University and LUMC have received funding from Open Science NL. The aim is to make science more accessible to...
[Amsterdam, 15th December 2025] — Nikon BioImaging Lab Europe (NBIL) is delighted to announce that it has been honoured with the prestigious Deshima Award in the “Newcomer”...
The publication of the Wennink Report has led to extensive national and regional media coverage on the role of red biotechnology in the future of the Dutch economy and healthcare...